Skip to content

Evaluation of the effect of a single intake of protein hydrolysate on stress-related index

Evaluation of the effect of a single intake of protein hydrolysate on stress-related index -Placebo-controlled, randomized, double-blind, crossover study- - Evaluation of the effect of a single intake of protein hydrolysate on stress-related index -Placebo-controlled, randomized, double-blind, crossover study-

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049730
Enrollment
48
Registered
2022-12-13
Start date
2022-12-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult male and female

Interventions

Take three capsules containing protein hydrolysate per dose. Take three capsules without protein hydrolysate per dose. Take five capsules containing protein hydrolysate per dose. Take five capsules wi

Sponsors

IMEQRD Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy males and females from 20 to 50 years of age at the time of obtaining consent to participate in this study. 2)Participants who can input data into the logbook using electronic tools such as a PC, or smarthone. 3)Participants can make self-judgment and are voluntarily giving written informed consent.

Exclusion criteria

Exclusion criteria: Participants have a disease that mental and physical disorders. Participants have been diagnosed with a cognitive processing disorder. Participants have undergone gastrointestinal surgery (excluding appendicitis). Participants are currently taking over-the-counter drugs, foods for specified health uses, supplements, etc, or who cannot stop taking supplements during the study period. Participants take food for specified health use, energy drinks, etc, that aim to have effects on the autonomic nervous system, etc. Participants drink a lot of alcohol. Participants have a smoking habit (Participants less than one year after quitting smoking). Participants with irregular life rhythms (shift work, etc.). Participants may change their lifestyle during the examination period. Participants have a life event that affects their mind and body within the past month. Participants participated in a study involving the use of other foods or drugs, or the application of cosmetics or drugs within one month before obtaining consent, or who will participate in another study while participating in this study. Participants consume a large amount of dairy products, etc, every day. Participants have a habit of doing strenuous exercise at least 3-4 times a week. Participants have experienced poor mood or deterioration of physical condition due to blood collection. Participants are currently undergoing regular hospital visits and treatment for any illness. Participants have severe diseases in the liver, heart, metabolic system, etc. Participants have a history of treatment for heart failure, etc. Participants may exhibit allergy symptoms to milk or soy, or have a lactose intolerant constitution. Participants with current or past drug or food allergies. Participants are currently pregnant or breastfeeding, and who wish to become pregnant during the study period. Others subjects are judged to be inappropriate as research subjects by the principal investigator.

Design outcomes

Primary

MeasureTime frame
POMS 2 short version (Japanese translation)

Secondary

MeasureTime frame
Uchida-Kraepelin test (correct answer rate) Assessment test of cognitive function Questionnaire for fatigue symptoms Salivary stress markers

Countries

Japan

Contacts

Public ContactRyo Uchida

Ajinomoto Co., Inc. Functional Ingredients Development Group, Wellness Value Creation Center, Institute of Food Sciences

ryo.uchida.xs6@asv.ajinomoto.com0442105844

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026